暨南大学附属复大肿瘤医院临床试验中心
注射用重组改构肿瘤坏死因子（天恩福）治疗恶性肿瘤的IV期临床研究
由上海唯科生物制药有限公司申办的“注射用重组改构人肿瘤坏死因子（天恩福）治疗恶性肿瘤的安全性及有效性的多中心 研究”正在南京、北京、上海、杭州、广州、福建等80-100家医院展开，将有2000例恶性肿瘤患者受益。
肿瘤坏死因子α（TNF-α）是迄今为止发现的抗肿瘤作用最强的细胞因子，是所有细胞因子中唯一具有直接杀伤肿瘤细胞的因子。注射用重组改构肿瘤坏死因子（rmhTNF-NC）是对TNF-α结构改造后的升级产品，于2004年上市销售，其联合化疗治疗非小细胞肺癌和非霍奇金淋巴瘤具有积极的疗效。
如果您或您的朋友是：年龄在18-75岁，非小细胞肺癌患者，并有意愿接受相应的治疗，您可以加入上海唯科生物制药有限公司在暨南大学附属复大肿瘤医院开展的“注射用重组改构人肿瘤坏死因子（天恩福）的IV期临床研究”。
如您希望了解更多详细信息，可通过以下联系方式进行咨询，您将获得更为详细的解答。
我们真诚地祝您早日康复！
Clinical Trial Center of Fuda Cancer Hospital affiliated to Jinan University
Phase IV clinical study of rmhTNF-NC (TianEnFu) for treating malignant tumors
A multi-center study on the safety and efficacy of rmhTNF-NC (TianEnFu) for treating malignant tumors applied by Shanghai WeikeBio-Pharmaceutical Co., Ltd. is conducted in 80-100 hospitals in Nanjing, Beijing, Shanghai, Hangzhou, Guangzhou and Fujian, etc. so 2,000 patients with malignant tumors can benefit from this study.
Tumor necrosis factor α (TNF-α) is the most potent anti-tumor cytokine to date, and is the only factor among all cytokines that directly kill tumor cells. Marketed in 2004, rmhTNF-NC is an upgraded product after structural modification of TNF-α with a positive effect on non-small cell lung cancer and non-Hodgkin's lymphoma with a combination of chemotherapy.
If you are or your friend is: aged 18-75,non-small cell lung cancer patient, and willing to receive appropriate treatment, please join phase IV clinical study of rmhTNF-NC (TianEnFu) conducted by Shanghai Weike Bio-Pharmaceutical Co., Ltd. in Fuda Cancer Hospital affiliated to Jinan University.
If you want more details, please feel free to contactus in 0086-20-38993956.
We sincerely wish you get well soon!
联系电话：4006680120
我们真诚地祝您早日康复！
联系人：梁红光 （肿瘤科）
电话/微信：18520088506
地址：广州市海珠区聚德中路91号暨南大学附属复大肿瘤医院八楼